MA28217A1 - Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3 - Google Patents

Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3

Info

Publication number
MA28217A1
MA28217A1 MA29068A MA29068A MA28217A1 MA 28217 A1 MA28217 A1 MA 28217A1 MA 29068 A MA29068 A MA 29068A MA 29068 A MA29068 A MA 29068A MA 28217 A1 MA28217 A1 MA 28217A1
Authority
MA
Morocco
Prior art keywords
acetylcholine receptor
muscarinic acetylcholine
novel antagonists
novel
antagonists
Prior art date
Application number
MA29068A
Other languages
English (en)
Inventor
Jakob Busch-Petersen
Jin Jian
R Palovich Michael
Fu Wei
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34676665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA28217A1 publication Critical patent/MA28217A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Antagonistes nouveaux du récepteur d'acétylcholine rauscarinique M3 Des antagonistes du récepteur d'acétylcholine muscarinique et des méthodes pour leur utilisation sont proposés.
MA29068A 2003-12-03 2006-06-02 Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3 MA28217A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52682403P 2003-12-03 2003-12-03

Publications (1)

Publication Number Publication Date
MA28217A1 true MA28217A1 (fr) 2006-10-02

Family

ID=34676665

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29068A MA28217A1 (fr) 2003-12-03 2006-06-02 Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3

Country Status (17)

Country Link
US (1) US20070179184A1 (fr)
EP (1) EP1708702A2 (fr)
JP (1) JP2007513181A (fr)
KR (1) KR20060123415A (fr)
AR (1) AR046784A1 (fr)
AU (1) AU2004296207A1 (fr)
BR (1) BRPI0417215A (fr)
CA (1) CA2549272A1 (fr)
IL (1) IL175995A0 (fr)
IS (1) IS8515A (fr)
MA (1) MA28217A1 (fr)
MX (1) MXPA06006372A (fr)
NO (1) NO20062992L (fr)
PE (1) PE20050897A1 (fr)
UY (1) UY28645A1 (fr)
WO (1) WO2005055940A2 (fr)
ZA (1) ZA200604395B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
EP1677796A4 (fr) * 2003-10-17 2006-12-27 Glaxo Group Ltd Antagonistes du recepteur acetylcholine muscarinique
AR046225A1 (es) * 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
US20090253908A1 (en) * 2004-03-11 2009-10-08 Glaxo Group Limited Novel m3 muscarinic acetylchoine receptor antagonists
EP1725564A4 (fr) * 2004-03-17 2007-09-12 Glaxo Group Ltd Antagonistes du recepteur d'acetylcholine muscarinique m3
WO2005094251A2 (fr) * 2004-03-17 2005-10-13 Glaxo Group Limited Antagonistes du recepteur muscarinique a l'acetylcholine m3
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
EP1747219A4 (fr) * 2004-05-13 2010-05-26 Glaxo Group Ltd Domaine de l'invention antagonistes récepteurs d'acétyle choline muscarinique
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000481A (es) 2004-07-14 2007-03-29 Ptc Therapeutics Inc Metodos para tratar hepatitis c.
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN101022802A (zh) 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
EP1778229A4 (fr) * 2004-08-10 2009-06-17 Incyte Corp Composes amido et leur utilisation comme produits pharmaceutiques
EP1957075A4 (fr) * 2004-11-15 2009-11-18 Glaxo Group Ltd Nouveaux antagonistes des recepteurs muscariniques de type m3 de l'acetylcholine
US20080275079A1 (en) * 2005-08-02 2008-11-06 Glaxo Group Limited M3 Muscarinic Acetylcholine Receptor Antagonists
JP2009504768A (ja) * 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
EP1089980A1 (fr) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Composes d'inhibition de la liberation du peptide beta-amyloide et/ou de sa synthese
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases

Also Published As

Publication number Publication date
BRPI0417215A (pt) 2007-02-21
ZA200604395B (en) 2007-10-31
KR20060123415A (ko) 2006-12-01
EP1708702A2 (fr) 2006-10-11
UY28645A1 (es) 2005-06-30
MXPA06006372A (es) 2006-08-23
JP2007513181A (ja) 2007-05-24
AU2004296207A1 (en) 2005-06-23
CA2549272A1 (fr) 2005-06-23
IS8515A (is) 2006-06-19
US20070179184A1 (en) 2007-08-02
AR046784A1 (es) 2005-12-21
IL175995A0 (en) 2006-10-05
NO20062992L (no) 2006-06-27
WO2005055940A3 (fr) 2005-09-15
PE20050897A1 (es) 2005-11-06
WO2005055940A2 (fr) 2005-06-23

Similar Documents

Publication Publication Date Title
MA28217A1 (fr) Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3
MA28218A1 (fr) Nouveaux antagonistes de recepteur d'acetylcholine muscarinique m3
MA28110A1 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
MA27900A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA27973A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA27901A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA28109A1 (fr) Antagonistes du recepteur acetylcholine muscarinique
CY1113295T1 (el) Ανταγωνιστες m3 μουσκαρινικου υποδοχεα ακετυλοχολινης
MY144753A (en) Muscarinic acetylcholine receptor antagonists
WO2004012684A3 (fr) Antagonistes des recepteurs de l'acetylcholine muscarinique m3
MA29080B1 (fr) Derives de la quinuclidine et leur utilisation en tant qu'antagonistes du recepteur m3 muscarinique
FR2814678B1 (fr) Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
GB0504828D0 (en) Therapeutic agents
ATE551850T1 (de) Verfahren und system zum bereitstellen von positionsinformationen und rückrufeinrichtung
FR2872511B1 (fr) Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique
FR2864404B1 (fr) Generateur d'un signal pour la television analogique ou la television numerique